報價延遲最少15分鐘:2026/06/10 17:01 EDT
盤後時段
|
||||
|
89.47 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
89.47
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-8.39/-2.14
|
|
企業價值
1.41B
|
| 資產負債 |
|
每股賬面淨值
-1.43
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.30M
|
|
每股收益
0.04
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function. |
